Vedolizumab IV
Vedolizumab IV is a pharmaceutical drug with 12 clinical trials. Currently 6 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 4 completed trials
Phase Distribution
Phase Distribution
1
Early Stage
0
Mid Stage
10
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
80.0%
4 of 5 finished
20.0%
1 ended early
6
trials recruiting
12
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting
Expanded Access to Vedolizumab for Children and Teenagers With Ulcerative Colitis or Crohn's Disease in the USA
Clinical Trials (12)
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
A Study of Vedolizumab in Adults With Ulcerative Colitis or Crohn's Disease in the Community Setting
Expanded Access to Vedolizumab for Children and Teenagers With Ulcerative Colitis or Crohn's Disease in the USA
Efficacy and Safety of Vedolizumab IV in Chinese Participants With Ulcerative Colitis
A Study of Vedolizumab in Adult Participants With Moderate to Severe Crohn's Disease
A Study of Vedolizumab in People With Ulcerative Colitis and Crohn's Disease
Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis
Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease.
A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis
Bioavailability and Pharmacokinetics of Vedolizumab in Healthy Participants Following Single Subcutaneous Administration
All 12 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 12